Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AGLTS:0VRQ +3.07%46 Cash Ratio is 17.79 as of Jun. 2026, which is 8% above its 10-year median of 16.48. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 and a GF Value™ of $4.36 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,379 Biotechnology companies, CRISPR Therapeutics AG ranks better than 91.08% on this metric.
CRISPR Therapeutics AG has a Cash Ratio of 17.79. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for CRISPR Therapeutics AG's Cash Ratio or its related term are showing as below:
LTS:0VRQ'
s Cash Ratio Range Over the Past 10 Years
Min: 2.93 Med: 16.48 Max: 25.91
Current: 17.79
During the past 12 years, CRISPR Therapeutics AG's highest Cash Ratio was 25.91. The lowest was 2.93. And the median was 16.48.
LTS:0VRQ's Cash Ratio is ranked better than 91.08% of 1379
companies
in the Biotechnology industry
Industry Median: 2.93
vs LTS:0VRQ: 17.79
CRISPR Therapeutics AG (LTS:0VRQ) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs MANE, EWTX, CAI: Cash Ratio Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cash Ratio distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a Cash Ratio of 17.79 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CRISPR Therapeutics AG and its competitors. This is near median its historical median of 16.48. Over the past decade, CRISPR Therapeutics AG's Cash Ratio has ranged from 2.93 to 25.91. According to the industry distribution chart, CRISPR Therapeutics AG ranks #123 out of 1379 companies in the Biotechnology industry, placing it in the top 8.9%.
Is CRISPR Therapeutics AG's Cash Ratio too high?
CRISPR Therapeutics AG's current Cash Ratio of 17.79 is near median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 25.91. The Biotechnology industry median Cash Ratio is 2.93. CRISPR Therapeutics AG's value of 17.79 is 507.2% above this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #123 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cash Ratio compare to MANE and EWTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #123 out of 1379 companies for Cash Ratio. This places CRISPR Therapeutics AG in the top 9% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. CRISPR Therapeutics AG's value of 17.79 is 507.2% above this benchmark. Historically, CRISPR Therapeutics AG's own Cash Ratio has ranged from 2.93 to 25.91 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 2.93, CRISPR Therapeutics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Cash Ratio of 17.79 is 507.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Cash Ratio is 17.79, which is near median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $53.75 — trading 1132.8% above its estimated fair value. The current Cash Ratio is 17.79, which is near median its 10-year median of 16.48 and 507.2% above the Biotechnology industry median of 2.93. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Cash Ratio is 17.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $53.75 is trading 1132.8% above its estimated GF Value™ of $4.36.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
Cash Ratio: 17.79 (near median its 10-year median of 16.48)
GF Value™: $4.36 vs. price of $53.75 (1132.8% above fair value)
Industry Position: 507.2% above the Biotechnology median (#123 of 1379)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score
Get the complete analysis for LTS:0VRQ
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
